Enanta Pharmaceuticals, Inc. is a pharmaceutical company based in the United States that specializes in researching and developing molecule drugs to treat viral infections and liver diseases. With a medium risk ESG score of 24.9, the company focuses on diseases such as hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. Enanta Pharmaceuticals is known for its specific direct-acting antiviral inhibitor against the hepatitis C virus, developed in collaboration with AbbVie. Their innovative inhibitors, including paritaprevir, are making waves in the industry.